Codexis
NASDAQ: CDXSRedwood City, US · 3 known investors
Codexis provides enzyme engineering and biocatalysis services for RNA and small molecule API manufacturing, offering RNAi/siRNA and enzymatic synthesis solutions to pharmaceutical partners. It supports customers from process development through scalable commercial supply using an in-house pilot plant and CMO network.
Founders & leadership
GS
Gordon SangsterinCFO2014–2019
JN
John NicolsinPresident & CEO2012–2022
DS
David SmithNamed on SEC filing
Board
TB
Thomas BaruchBoard director
PC
Pam ChengBoard director
KG
Kathleen GlaubBoard director
BK
Bernard KelleyBoard director
BD
Byron DorganBoard director
PY
Patrick YangBoard director
DW
Dennis WolfBoard director
Investors · 3
Also in the syndicate · 2
Cantor Fitzgerald & Co.Piper Sandler & Co.
Funding
SEC filings, press & company announcements$50M disclosed across 1 of 3 rounds · 2019–2026
- Undisclosed amountpublic offeringJul 2026
Cantor Fitzgerald & Co., Piper Sandler & Co.
Source ↗
▶$50MraisedJun 2019 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gordon SangsterExecutive Officer
- John NicolsExecutive Officer, Director
- Pam ChengDirector
- Kathleen GlaubDirector
- Bernard KelleyDirector
- Byron DorganDirector
- Thomas BaruchDirector
- Patrick YangDirector
- Dennis WolfDirector
- David SmithDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
5 people who came through Codexis went on to found or lead other companies.
Ryan MartineauCorporate StrategyFounded Redaptive +1Gjalt HuismanSenior Vice President, Strategic Development; General Manager, BiotherapeuticsFounded Embold TherapeuticsFrances H. ArnoldAdvisorFounded ProviviEzhil SubbianScientist II & Technical LeadFounded StringbioAlan ShawFounder, President & CEO, BoardFounded Calysta
Competitors · 2
by search overlap
Exelixis34 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
LeadIQ19 shared keywordsLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.
Companies competing with Codexis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Codexis Affirms FY26 Sales Guidance Range Amid Stable Outlookscanx.trade · Aug 2026
Codexis Q2 Earnings Call Highlightsfinance.yahoo.com · Aug 2026
Codexis posts higher 2026 revenue but stays in loss | CDXS Quarterly Report (10-Q)stocktitan.net · Aug 2026
Codexis narrows Q2 loss, raises $25M to fund GMP expansionscanx.trade · Aug 2026Frequently asked questions
- What does Codexis do?
- Codexis provides enzyme engineering and biocatalysis services for RNA and small molecule API manufacturing, offering RNAi/siRNA and enzymatic synthesis solutions to pharmaceutical partners. It supports customers from process development through scalable commercial supply using an in-house pilot plant and CMO network.
- Who are Codexis's investors?
- Codexis's investors include Baruch Future Ventures.
- How much funding has Codexis raised?
- Codexis has disclosed $50M raised across 1 of its 3 known rounds.
- Where is Codexis headquartered?
- Codexis is headquartered in Redwood City, US.